NYXH

Tempus AI (TEM) reported quarterly earnings of $0.07 per share, beating consensus estimates of a loss of $0.09, representing a 177.78% earnings surprise. The company posted revenues of $411.54 million, surpassing estimates by 0.05% and showing year-over-year growth from $334.21 million.

However, the stock received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market. The Medical Info Systems industry ranks in the top 36% of Zacks industries.

Nyxoah reported Q3 2026 global net revenue of €9.2 million with 29% sequential U.S. growth, but lowered full-year 2026 revenue guidance to €33-35 million from €36-40 million. The company submitted a PMA supplement to expand its Genio hypoglossal nerve stimulation system to Complete Concentric Collapse patients, with the ACCCESS study meeting efficacy endpoints at 77.2% AHI responder rate.

Nyxoah reported Q3 2026 net revenue of €9.2 million with 29% sequential growth in US sales. The company submitted a PMA supplement to the FDA to expand Genio's indication to complete concentric collapse patients, with the ACCCESS study meeting primary efficacy endpoints (77.2% responder rate). However, full-year 2026 revenue guidance was lowered to €33-35 million from €36-40 million.

Schrodinger shares surged 7.6% to close at $32.6, driven by investor optimism following the announcement of Tectora, a new biotech company co-founded by Schrodinger, NEA, and RA Capital Management focused on immunology and inflammation therapies. The company secured $55 million in Series A funding.

Despite expected quarterly losses of $0.66 per share and a 15.3% revenue decline, consensus EPS estimates have been revised 72.2% higher over the past 30 days, suggesting potential for continued strength. SDGR carries a Zacks Rank #3 (Hold).